Analysis and recommendations for agency action regarding nonsteroidal antiinflammatory drugs and cardiovascular risk.
On April 6, 2005, the Directors of the Office of New Drugs and the Office of Pharmacoepidemiology and Statistical Science at the U. S. Food and Drug Administration posted the following information on the FDA website pertaining to analysis and recommendations for FDA action regarding nonsteroidal anti-inflammatory drugs and cardiovascular risk.
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects* / Q000592:standards*; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects / Q000592:standards; D006801:Humans; D004366:Nonprescription Drugs / Q000592:standards; D011356:Product Labeling / Q000331:legislation & jurisprudence; D011358:Product Surveillance, Postmarketing / Q000592:standards; D018570:Risk Assessment; D014481:United States; D014486:United States Food and Drug Administration
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D004366:Nonprescription Drugs